Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Neutral
0.0
The highest dose of Eli Lilly's weekly injection helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
